Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung …

YT Lin, JS Chen, WY Liao, CC Ho… - … Journal of Cancer, 2019 - Wiley Online Library
Gefitinib, erlotinib and afatinib are approved for first‐line treatment of advanced non‐small
cell lung cancer (NSCLC) bearing an activating epidermal growth factor receptor (EGFR) …
被引用次数：60 相关文章

Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung …

YT Lin, JS Chen, WY Liao, CC Ho, CL Hsu… - … Journal of Cancer, 2019 - europepmc.org
Gefitinib, erlotinib and afatinib are approved for first-line treatment of advanced non-small
cell lung cancer (NSCLC) bearing an activating epidermal growth factor receptor (EGFR) …

Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung …

YT Lin, JS Chen, WY Liao, CC Ho… - … journal of cancer, 2019 - pubmed.ncbi.nlm.nih.gov
Gefitinib, erlotinib and afatinib are approved for first-line treatment of advanced non-small
cell lung cancer (NSCLC) bearing an activating epidermal growth factor receptor (EGFR) …

[引用][C] Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small …

YT Lin, JS Chen, WY Liao, CC Ho, CL Hsu… - International Journal of …, 2019 - cir.nii.ac.jp
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation
among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung cancer patients …